Perspectives on Surrogate End Points in the Development of Drugs that Reduce the Risk of Cancer

• Published in: Cancer epidemiology, biomarkers & prevention Vol. 9; no. 2; pp. 127 - 137
• Main Authors: KELLOFF, G. J, SIGMAN, C. C, JOHNSON, K. M, BOONE, C. W, GREENWALD, P, CROWELL, J. A, HAWK, E. T, DOODY, L. A
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.02.2000
• Subjects: Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Biomarkers, Tumor - analysis; Cell Transformation, Neoplastic; Chemoprevention; Chemotherapy; Drug Design; Humans; Medical sciences; Neoplasms - prevention & control; Pharmacology. Drug treatments; Research Design; Treatment Outcome; Human; Drug; Biological marker; Genotype; Malignant tumor; Carcinogenesis; Epidemiology; Incidence; Prevention; Chemotherapy; Perspective; Phenotype; Treatment; Bibliographic review; Public health

This paper proposes a scientific basis and possible strategy for applying surrogate end points in chemopreventive drug development. The potential surrogate end points for cancer incidence described are both phenotypic (at the tissue, cellular, and molecular levels) and genotypic biomarkers. To estab...